<DOC>
	<DOCNO>NCT00003880</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy gene therapy use SCH-58500 may kill tumor cell . PURPOSE : Randomized phase II/III trial determine effectiveness paclitaxel plus carboplatin without SCH-58500 treat patient newly diagnose stage III ovarian stage III primary peritoneal cancer residual disease follow surgery remove tumor .</brief_summary>
	<brief_title>Paclitaxel Plus Carboplatin With Without SCH-58500 Treating Patients With Newly Diagnosed Stage III Ovarian Stage III Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess effect paclitaxel carboplatin without SCH 58500 progression free survival , overall survival , safety , response , CA-125 level patient newly diagnose stage III ovarian epithelial primary peritoneal cancer . OUTLINE : This randomize , open label , multicenter study . Patients receive treatment IV paclitaxel IV carboplatin . Patients randomize one two treatment group : Arm I : Patients receive IV paclitaxel 3 hour , immediately follow IV carboplatin , day 1 . Courses repeat every 21 day . Arm II : Patients receive IV paclitaxel 3 hour , immediately follow IV carboplatin , day 1 . Patients receive intraperitoneal SCH 58500 day 1-5 . Courses repeat every 21 day . Patients follow every 6 week 36 month , every 3 month 2 year , every 6 month disease progression . PROJECTED ACCRUAL : A total 360 patient ( 180 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III ovarian epithelial primary peritoneal cancer residual disease great 2 cm follow cytoreductive surgery The follow cell type eligible : Serous adenocarcinoma , mucinous adenocarcinoma , clear cell adenocarcinoma , transitional cell , adenocarcinoma NOS , endometrioid adenocarcinoma , mixed epithelial carcinoma , peritoneal serous papillary carcinoma Total abdominal hysterectomy salpingooophorectomy supracervical hysterectomy , omentectomy , tumor reduction , lymph node assessment , debulking node 2 cm great No endometrial malignancy treat supracervical hysterectomy No cytologically positive pleural effusion No tumor borderline histology No cancer fallopian tubes PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2 mg/dL Glomerular filtration rate le 30 Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception No serious medical condition No prior malignancy except carcinoma situ cervix , nonmelanomatous skin cancer , Dukes A colorectal cancer patient disease free past 5 year , stage I II breast cancer patient disease free past 10 year PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent cytokine therapy allow Chemotherapy : No 1 prior chemotherapy course ovarian peritoneal cancer At least 10 year since prior adjuvant chemotherapy breast cancer Endocrine therapy : At least 3 month since prior systemic corticosteroid immunosuppressive therapy Concurrent female hormonal replacement allow Radiotherapy : No prior radiotherapy ovarian peritoneal cancer No prior radiotherapy abdomen Surgery : Prior surgery allow Other : No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>